NICE· @NICEComms · X·· 14 天前精选AI 评分60
AI 导读
NICE 发布最终指南，推荐 mirdametinib 用于部分无法手术的儿童和青少年罕见神经肿瘤患者，约 200 名患者有望受益。该指南为 mirdametinib 在手术不可行情况下的使用提供了选项，详情见 https://www.nice.org.uk/guidance/ta1192。
推荐理由
NICE 最终指南将 mirdametinib 纳入特定儿童神经肿瘤人群，可了解其适用条件与受益规模。
正文
Around 200 children and young people with rare nerve tumours are set to benefit after we published final guidance recommending a new treatment today.
Mirdametinib is an option for some families when surgery isn't possible.
Find out more: https://www.nice.org.uk/guidance/ta1192
来源：NICE · x.com